According to filings with the U.S. Securities and Exchange Commission, Inner Logic fka Semaphor has raised $11,500,000.00 in new Seed funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: General Catalyst, Bison Ventures, J2VP, Defined, PTX, Valia Ventures, Page One, Alumni Ventures, Flare

About Inner Logic fka Semaphor
Inner Logic (formerly known as Semaphor) is a medical technology company that provides development and simulation infrastructure for the next generation of procedural devices, including orthopedic implants, heart valves, and surgical robots. Based on the content of its homepage, the company focuses on enabling device manufacturers to design, test, and validate these complex procedural devices in software-defined, cloud-based simulation environments, reducing reliance on traditional cadaver labs and animal studies. It positions itself as core infrastructure for autonomous and intelligent procedural medical devices, aiming to accelerate development cycles so teams can move from concept to production in dramatically shorter timeframes while improving device performance and surgical outcomes. Inner Logics platform is built for manufacturers who need to evaluate devices across large numbers of virtual patients grounded in real procedural data, highlighting its role at the intersection of advanced software, robotics, and clinical practice. As the evolution of Semaphor, Inner Logic presents itself as a foundational technology provider for the emerging market of autonomous procedural devices, serving leading innovators who require scalable, high-fidelity simulation to bring safer, more capable medical devices to market.

To learn more, visit https://innerlogic.io/
Linkedin: https://www.linkedin.com/company/inner-logic-io

Contact:
Tito Porras, Chief Executive Officer
https://www.linkedin.com/in/titoporras/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.